Modality
mAb (human IgG4)
Mechanism
Blocks IL-4Rα — dual IL-4 and IL-13 signaling
Targets
IL-4Rα
Storage
refrigerated 2–8 °C
Approved
atopic dermatitis — FDA 2017 · prurigo nodularis — FDA 2022 · bullous pemphigoid — FDA 2025
In trial
chronic spontaneous urticaria, hand eczema
Pregnancy
no human data; animal studies not suggestive
Monitoring
baseline eye exam if conjunctivitis history
Last verified
2026-04-14
Mechanism of action
Dupixent label (FDA, 2024)drugtargetsignalingeffectorcellularphenotype⊣ red bar = blocked/reduced by drug
Monitoring & workup
Baseline workup
- •TB IGRA (or PPD)
- •HBV sAg if high risk; HCV Ab if high risk
- •Update age-appropriate vaccines before start
Ongoing monitoring
- •No routine labs
- •Annual TB screening if high exposure risk
- •IL-17 class: monitor for candida overgrowth + IBD flare
- •IL-23 class: monitor for injection-site reactions